Other
Japan Adult Leukemia Study Group
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
Failure Rate
0.0%
0 terminated/withdrawn out of 3 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Phase 2
2(66.7%)
Phase 3
1(33.3%)
3Total
Phase 2(2)
Phase 3(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT00131053Phase 2Unknown
Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)
Role: lead
NCT00131027Phase 3Unknown
High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)
Role: lead
NCT00130195Phase 2Completed
Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)
Role: lead
All 3 trials loaded